Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013020 | 0.80 | ALOX15 (0.40) | PRKCAALDH1A1BTN3A1 | |
| SCHEMBL449290 | 0.78 | ALDH1A1 (0.31) | PRKCAALDH1A1 | |
| SCHEMBL4156482 | 0.78 | PRKCA (0.31) | PRKCA | |
| SCHEMBL10431807 | 0.76 | — | — | |
| SCHEMBL451530 | 0.75 | TSHR (0.36) | PRKCAALDH1A1 | |
| SCHEMBL27501595 | 0.73 | PRKCA (0.32) | PRKCA | |
| SCHEMBL450817 | 0.73 | CYP1A2 (0.39) | — | |
| SCHEMBL450210 | 0.73 | ELANE (0.32) | PRKCA | |
| SCHEMBL6921711 | 0.73 | PRKCA (0.36) | PRKCABTN3A1 | |
| SCHEMBL10990412 | 0.72 | EP300 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | disclosed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | disclosed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5886179-A | NUCLEOTIDE PHOSPHONATE ESTERS HYDROLYZABLE IN VIVO TO THE CORRESPONDING NUCLEOTIDE PHOSPHONATE AS VIRICIDES | GILEAD SCIENCES, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0874858-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5798340-A | ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY | GILEAD SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997024361-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | PRKCA 1085/4885ALDH1A1 4101/4885BTN3A1 3288/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | PRKCA 1085/4885ALDH1A1 4101/4885BTN3A1 3288/4885 |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | PRKCA 1085/4885ALDH1A1 4101/4885BTN3A1 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.